Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (TOPICAL)

This study has been completed.
Sponsor:
Collaborators:
Cancer Research UK
Roche Pharma AG
Information provided by (Responsible Party):
University College, London
ClinicalTrials.gov Identifier:
NCT00275132
First received: January 10, 2006
Last updated: December 1, 2014
Last verified: December 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2009
  Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)